Arrow Electronics and SiMa.ai Enter Distribution Agreement in EMEA
28.5.2024 18:00:00 EEST | Business Wire | Press release
Global technology provider Arrow Electronics and SiMa.ai, the software centric, embedded edge machine learning system-on-chip company, have entered into a strategic collaboration, enabling Arrow to distribute SiMa.ai products in the EMEA region.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240528873376/en/
SiMa.ai’s Machine Learning System-on-Chip MLSoC (Photo: Business Wire)
SiMa.ai delivers one platform for all edge AI that scales with customers as their AI/ML projects evolve, from computer vision, to transformers to multimodal generative AI. The SiMa.ai MLSoC (Machine Learning System on Chip) enables full pipeline deployment of complete real-world workloads as a standalone edge-based system, with high performance and power efficiency.
SiMa.ai’s MLSoC works seamlessly with Palette Software to support customers across multiple verticals such as industrial manufacturing, retail, aerospace, defense, agriculture, and healthcare, with increased compute capabilities, while maximizing efficiency by delivering the highest frames per second per watt (FPS/W) performance in the edge AI/ML market.
With this agreement, Arrow and SiMa.ai will jointly market SiMa.ai’s offerings and Arrow will serve as the region’s exclusive distributor for the SiMa.ai MLSoC, SiMa.ai Palette Software and SiMa.ai Development Kits.
Margit Tischler, vice president of engineering in EMEA for Arrow, said, “At Arrow, we recognise the importance of artificial intelligence at the edge. SiMa.ai extends our AI line card, allowing us to offer our customers a solution tailored to their specific AI needs.”
“We are pleased to enter this distribution agreement with Arrow, which will speed access for customers throughout Europe and the Middle East to SiMa.ai’s one platform for all edge AI — and will support customers as their AI/ML journeys evolve — from computer vision to transformers to multimodal generative AI,” said Elizabeth Samara-Rubio, chief business officer, SiMa.ai. “This agreement with Arrow will help SiMa.ai scale further to meet rising customer demand as organizations increasingly need a partner to help them deploy and scale AI/ML workloads at the edge.”
Arrow will showcase SiMa.ai in its booth (at Stand J1) at Hardware Pioneers Max in London from 28 to 29 May, 2024. In addition, SiMa.ai will be participating in a talk with Arrow at Hardware Pioneers Max titled, “Accelerate the Entire Vision Pipeline,” which will explore the practical roadmap of machine learning and AI in key end applications on 29.5.24 in Conference Room 1, from 10:40 - 11:10.
For more information on how SiMa.ai can help accelerate edge ML projects, prospective customers can register for the Arrow webinar featuring SiMa.ai on 10th June, 2024 by clicking here or book an AI Consultation with Arrow Experts.
About Arrow Electronics:
Arrow Electronics guides innovation forward for thousands of leading technology manufacturers and service providers. With 2023 sales of $33 billion, Arrow develops technology solutions that help improve business and daily life. Learn more at arrow.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240528873376/en/
Contact information
Thorsten Hecking
thorsten.hecking@arrow.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom